Invesco BLDRS Developed Markets 100 ADR Index Fund

Latest Invesco BLDRS Developed Markets 100 ADR Index Fund News and Updates

  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Was Flat in Second Quarter

    GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates

    Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Established Prescription Products in 4Q17

    Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///BIOVERATIV_TXN_HIGHLIGHTS
    Company & Industry Overviews

    Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights

    On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    GSK Has Emerged as Leading Player in Over-the-Counter Market

    GlaxoSmithKline (GSK) is currently the leader in the 135 billion pound consumer healthcare market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GSK Is Focused on Innovative Assets in Oncology Research Pipeline

    In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    AstraZeneca’s 4Q17 Estimates: Segment Revenues

    AstraZeneca’s (AZN) cardiovascular and metabolics diseases segment’s revenues are expected to decrease in 4Q17 due to lower sales of Crestor and Byetta.

    By Mike Benson
  • uploads///Analysts
    Company & Industry Overviews

    Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018

    In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.

    By Daniel Collins
  • uploads///Nexium
    Company & Industry Overviews

    How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017

    In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

    By Daniel Collins
  • uploads///Chart  GSK
    Miscellaneous

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Vaccines Business Expected to Boost Sanofi’s Revenues in 2017

    In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.

    By Margaret Patrick
  • uploads///Chart  Consumer
    Earnings Report

    GSK’s 2Q17 Earnings: Consumer Healthcare

    GlaxoSmithKline (GSK) reported flat international revenues at constant exchange rates to 843.0 million pounds during 2Q17.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.